CareNet, Inc.（TSE 2015）
In addition to providing physicians and medical professionals with helpful information for day-to-day clinical practice via the internet, CareNet, Inc. provides pharmaceutical companies with solutions for effectively carrying out activities for disseminating pharmaceuticals information.
SanBio Co., Ltd.（TSE 4592）
SanBio Co., Ltd. develops, manufactures, and sells regenerative cell drugs for treating central nervous system injuries or diseases such as stroke or traumatic brain injury. Currently the company is aiming to realize breakthrough therapeutic drugs for treating chronic- phase stroke and traumatic brain injury.
Modalis Therapeutics Corporation
Possessing a powerful therapeutic drug creation platform based on the genome editing technology CRISPR, this bio-tech company aims to develop breakthrough therapeutic drugs for treating genetic diseases, which are said to number in excess of 6,000.
CellGenTech carries out practical development of adipocyte drugs for use in gene therapies incorporating therapeutic protein genes for the treatment of intractable diseases that occur due to congenital enzyme or functional protein deficiencies.
Gene Therapy Research Institution Co., Ltd.(Japan)
With the aim of providing world-leading gene therapies for intractable diseases for which no effective treatments have existed until now, Gene Therapy Research Institution Co., Ltd. is consistently pursuing R&D from basic research through to clinical research, with particular focus on Parkinson’s disease, Amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease. Using their revolutionary approach of employing extraordinarily safe adeno-associated viruses (AAV) as viral vectors to deliver therapeutic genes, the company is developing internationally competitive innovative gene therapies.
DiscGenics is a startup specializing in regenerative therapies for IVD tissue, which functions to provide a cushion for the spine. Expectations are raised for the possibility that development of regenerative therapies for IVD tissue using allogeneic stem cells derived from the IVD nucleus pulposus may offer a high cost-effective treatment modality without requiring major surgical intervention. DiscGenics is currently developing regenerative therapies for the approval in the US and Japan.